Sharma, Subodh Bn, Debasish Basu Introduction: Current UK guidelines, in line with many other countries, do not support routine antenatal screening for hepatitis C virus (HCV). At St Mary’s Hospital, UK all mothers attending antenatal screening are offered HCV testing. We discuss

the outcomes over the last 10 years. Methods: All pregnancies with antenatal booking dates from the 1st November 2003 to the 1st March 2013 were included for retrospective analysis. Records of patients with antenatal screening HCV positive results are stored on a maternity unit anonymised encrypted database. Data on these women from hospital reporting software and clinic

notes were used to make the audit BIBW2992 cell line dataset. Results: Within the audited Ipilimumab in vitro period a total of 35,455 women had booked in for antenatal care. A total of 119 (0.003%) HCV antibody positive results were recorded. 44 (37%) of these were new cases of HCV, as confirmed by PCR testing, 32 (27%) cases were in patients who had previously been diagnosed with HCV and 43 (36%) were spontaneous clearers. Of the newly diagnosed HCV mothers 10 reported a history of injecting drug use, 1 had possibly been infected via blood transfusion. 12 women were born in the United Kingdom and 32 born outside the UK. As of December 2013, 19 of the 44 newly diagnosed women underwent treatment for HCV and 2 are currently undergoing treatment, with 14 achieving SVR (74%). Of nine women

with genotype 1 HCV, eight were treated with interferon and ribavirin without protease inhibitor and one during a clinical trial involving alisporivir. 7 (78%) women with genotype 1 achieved SVR. Of the 23 women that currently haven’t been treated 20 are in active follow-up. All newly diagnosed women assessed with either liver biopsy or fibroscan had mild to moderate disease only. 4 vertical transmissions were identified MCE公司 from the 119 HCV antibody positive mothers (3.4% [95% CI 0.9-8.4%]). Out of the 44 deliveries by newly diagnosed mothers, 3 babies were infected vertically (6.8% [95%CI 1.4-18.7%]), as confirmed by PCR at 15 months of age. Conclusion: We demonstrate that antenatal screening provides an opportunity to identify healthy women infected with HCV at an early stage of their disease, who may not have otherwise been identified. Compliance to follow-up and SVR rates are superior to quoted rates in high-risk targeted groups. Disclosures: Claire Thorne – Grant/Research Support: AbbVie, Janssen, Public Health England, European Commission, PENTA Foundation Mark R. Thursz – Advisory Committees or Review Panels: Gilead, BMS, Abbott Laboratories Ashley S.